SEC Probes Aveo Over Failed Renal Cancer Drug
The Cambridge, Mass.-based company said it received a subpoena from the SEC on July 3 requesting documents and information concerning tivozanib, which the FDA in June declined to approve for the treatment of patients with advanced renal cell carcinoma.
Aveo said the SEC requested tivozanib-related communications with the FDA,...
Already a subscriber? Click here to login